GlaxoSmithKline's Immunotherapy For Endometrial Cancer Wins FDA Approval

The FDA has granted accelerated approval to GlaxoSmithKline plc's GSK Jemperli (dostarlimab) for endometrial cancer.
The approval covers patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR.
Jemperli targets the cellular pathway known as PD-1/PD-L1 (proteins found on the body's immune cells and some cancer cells). Jemperli helps the body's immune system in its fight against cancer cells by blocking this pathway.
The safety and efficacy of Jemperli was studied in a single-arm, multi-cohort clinical trial. Of the 71 patients in the Jemperli arm, 42.3% had a complete response (disappearance of tumor) or a partial response (shrinkage of tumor) to treatment with Jemperli. For 93% of responders, the response lasted for six months or more.
Price Action: GSK shares are down 1.45% at $37.69 in market hours on the last check Thursday.
Related content: Benzinga's Full FDA Calendar

Momentum46.74

Growth66.53

Quality15.86

Value25.47

Short

Medium

Long